微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
RSS 官方收录 · 可信分层展示
关键摘要
FDA批准首款靶向基因突变的胰腺癌新药，中位生存期延长6.5个月
- 革命药物公司胰腺癌新药获FDA批准，首攻遗传病因
- 临床试验显示二线治疗中位总生存期达13.2个月，较化疗提升6.5个月
- 特朗普政府将推新药价协议，多家中型生物技术公司参与 Medicaid折扣计划
AI 摘要 · 来源可核验
正文提要
Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy weather hovering over the Pharmalot campus right now, because our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is the mysterious witch’s brew. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …
The U.S. Food and Drug Administration approved a life-extending treatment for advanced pancreatic cancer made by Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy, STAT says. The approval was supported by a practice-changing clinical trial showing patients with advanced pancreatic cancer who received the drug as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients given standard chemotherapy.
The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, Bloomberg News reports. The companies will agree to provide discounts on outpatient drugs to state Medicaid programs so that the prices states pay align with what the companies charge in foreign countries. Participation by state Medicaid programs is optional. In exchange, the companies will be exempt from pilot programs forcing similar discounts in Medicare. Relief from tariffs is also part of some of the discussions.